Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
Biologic drug makers will soon have to alert the Federal Trade
Commission (FTC) and the U.S. Department of Justice (DOJ) of
agreements, including patent litigation settlements, they reach
with biosimilar applicants. The new reporting requirement is part
of the Patient Right to Know Drug Prices Act, which
President Trump signed into law on October 10, 2018. Read the
full Cooley alert
here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.